UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Twin Study Indicates Loss of Interaction Between Microbiota and Mucosa of Patients With Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2011-07, Vol.141 (1), p.227-236

2011

Volltextzugriff (PDF)

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active crohn's disease

Gastroenterology (New York, N.Y. 1943), 2001-05, Vol.120 (6), p.1339-1346

2001

Volltextzugriff (PDF)

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 Versus prednisolone in active crohn's disease

The American journal of gastroenterology, 2006-04, Vol.101 (4), p.793-797

2006

Volltextzugriff (PDF)

Recombinant Erythropoietin for the Treatment of Anemia in Inflammatory Bowel Disease

The New England journal of medicine, 1996-03, Vol.334 (10), p.619-624

1996

Volltextzugriff (PDF)

Combined α -methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease

Human pathology, 2009-02, Vol.40 (2), p.166-173

2009

Volltextzugriff (PDF)

Epidemiology of inflammatory bowel disease in a German twin cohort: Results of a nationwide study

Inflammatory bowel diseases, 2008-07, Vol.14 (7), p.968-976

2008

Volltextzugriff (PDF)

Certolizumab Pegol Is Efficacious in Crohnʼs Disease Patients Who Have Failed Infliximab Regardless of Concomitant Therapy or Reason for Failure: 1103

The American journal of gastroenterology, 2008-09, Vol.103, p.S430-S431

2008

Volltextzugriff (PDF)

Whole genome and exome sequencing of monozygotic twins discordant for Crohn's disease

BMC genomics, 2014-07, Vol.15 (1), p.564-564

2014

Volltextzugriff (PDF)

Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy

Inflammatory bowel diseases, 2011-02, Vol.17 (2), p.573-582

2011

Volltextzugriff (PDF)

Stress-Induced Gastrointestinal Secretory and Motor Responses in Rats Are Mediated by Endogenous Corticotropin-Releasing Factor

Gastroenterology (New York, N.Y. 1943), 1988-12, Vol.95 (6), p.1510-1517

1988

Volltextzugriff (PDF)

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

The Lancet (British edition), 1999-02, Vol.353 (9151), p.459-461

1999

Volltextzugriff (PDF)

Risk factors in German twins with inflammatory bowel disease: results of a questionnaire-based survey

Journal of Crohn's and colitis, 2012-02, Vol.6 (1), p.29-42

2012

Volltextzugriff (PDF)

THE ROLE OF THE MUCOSAL IMMUNE SYSTEM IN INFLAMMATORY BOWEL DISEASE

Gastroenterology clinics of North America, 1992-06, Vol.21 (2), p.451-502

1992

Volltextzugriff (PDF)

Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 1995-05, Vol.108 (5), p.1434-1444

1995

Volltextzugriff (PDF)

Mechanisms in failure of infliximab for Crohn's disease

The Lancet (British edition), 2000-10, Vol.356 (9240), p.1475-1479

2000

Volltextzugriff (PDF)

Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat

Gastroenterology (New York, N.Y. 1943), 1988-03, Vol.94 (3), p.598-602

1988

Volltextzugriff (PDF)

Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial

Clinical gastroenterology and hepatology, 2005-06, Vol.3 (6), p.581

2005

Volltextzugriff (PDF)

Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial

Clinical gastroenterology and hepatology, 2005-06, Vol.3 (6), p.581-586

2005

Volltextzugriff (PDF)

Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16

Gastroenterology (New York, N.Y. 1943), 1998-11, Vol.115 (5), p.1066-1071

1998

Volltextzugriff (PDF)

IL‐4 signaling mechanisms in inflammatory bowel disease mononuclear phagocytes

Inflammatory bowel diseases, 1996, Vol.2 (4), p.244-252

1996

Volltextzugriff (PDF)

Etiology of inflammatory bowel syndrome

International journal of colorectal disease, 2001-09, Vol.16 (5), p.269-270

Raedler, A

2001

Volltextzugriff (PDF)

Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 1995, Vol.108 (1), p.21-33

1995

Volltextzugriff (PDF)

494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-67-A-68

2008

Volltextzugriff (PDF)

Combined [alpha] -methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease

Human pathology, 2009-02, Vol.40 (2), p.166

2009

Volltextzugriff (PDF)

Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 1991-10, Vol.101 (4), p.1020-1030

1991

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(78)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(55)
Humans
(39)
Biological And Medical Sciences
(26)
Male
(24)
Female
(23)
Gastroenterology & Hepatology
(20)
Medical Sciences
(20)
Adult
(16)
Animals
(15)
Gastroenterology. Liver. Pancreas. Abdomen
(11)
Middle Aged
(11)
Inflammatory Bowel Disease
(10)
Other Diseases. Semiology
(10)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(10)
Adolescent
(8)
Crohn Disease - Drug Therapy
(7)
Pharmacology. Drug Treatments
(7)
Physical Sciences
(7)
Rats
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Twin Study Indicates Loss of Interaction Between Microbiota and Mucosa of Patients With Ulcerative Colitis

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active crohn's disease

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 Versus prednisolone in active crohn's disease

Recombinant Erythropoietin for the Treatment of Anemia in Inflammatory Bowel Disease

Combined α -methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease

Epidemiology of inflammatory bowel disease in a German twin cohort: Results of a nationwide study

Certolizumab Pegol Is Efficacious in Crohnʼs Disease Patients Who Have Failed Infliximab Regardless of Concomitant Therapy or Reason for Failure: 1103

Whole genome and exome sequencing of monozygotic twins discordant for Crohn's disease

Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy

Stress-Induced Gastrointestinal Secretory and Motor Responses in Rats Are Mediated by Endogenous Corticotropin-Releasing Factor

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

Risk factors in German twins with inflammatory bowel disease: results of a questionnaire-based survey

THE ROLE OF THE MUCOSAL IMMUNE SYSTEM IN INFLAMMATORY BOWEL DISEASE

Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease

Mechanisms in failure of infliximab for Crohn's disease

Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat

Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial

Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial

Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16

IL‐4 signaling mechanisms in inflammatory bowel disease mononuclear phagocytes

Etiology of inflammatory bowel syndrome

Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease

494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study

Combined [alpha] -methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease

Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease

Suchergebnisse filtern